IFRX
InflaRx N.V. Common StockstockNASDAQ
inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.24 | 2026-11-12 | -11.29% | -3.372 |
| 1M | 1.45 | 2026-10-19 | -24.14% | 0.694 |
| 3M | 2.12 | 2026-08-19 | -48.11% | 1.248 |
| 6M | 2.37 | 2026-05-19 | -53.59% | 1.276 |
| 1Y | 1.26 | 2025-11-19 | -12.70% | 1.581 |
| 2Y | 1.92 | 2024-11-19 | -42.71% | — |
| 5Y | 4.76 | 2021-11-19 | -76.89% | 0.826 |
InflaRx N.V. Common Stock (NASDAQ:IFRX) stock price today is $1.10, and today's volume is 3,047,841. IFRX is down 4.348% today. The 30 day average volume is 1.10M. IFRX market cap is $162.11M with 147.37M shares outstanding.